SAN DIEGO - September 12, 2013 (Investorideas.com newswire) Aethlon Medical, Inc. (
OTCBB:AEMD),
today announced the formal launch of Exosome Sciences, Inc. (ESI), a
wholly-owned subsidiary previously established by Aethlon to pursue
exosome-based strategies to diagnose and monitor the progression of
cancer, infectious disease and other life-threatening conditions.
Exosomes produced by diseased cells represent an optimal diagnostic
target as they are shed into bodily fluids such as urine and blood where
they can be easily accessed. Exosomes transport specific disease-origin
markers that provide the basis for ESI to establish non-invasive liquid
biopsies to diagnose and monitor a wide-range of disease conditions.
Aethlon Chairman and CEO, Jim Joyce stated, "As a therapeutic
organization, our primary focus is the clinical advancement and future
commercialization of the Aethlon Hemopurifer® in the United States and
abroad. With this mind, our objective with ESI is to transform a
currently dormant and unvalued diagnostic asset into a stand-alone
organization that contributes measurable asset value to Aethlon
shareholders, yet does not dilute our team's focus away from advancing
first-in-class therapeutic devices. It also became clear that the launch
of ESI might allow us to leverage recent valuations that have been
awarded to molecular diagnostic organizations with novel technology
strategies."
Aethlon disclosed that ESI's research facility is being established
within a CLIA certified laboratory located in Langhorne, Pennsylvania.
The facility is adjacent to the Philadelphia/New Jersey I-95 corridor,
which is the home for numerous U.S. biopharmaceutical organizations,
including Merck and Johnson & Johnson. The introduction of key ESI
researchers who will lead the development and commercialization of
next-generation diagnostics will occur through follow-on disclosures.
At present, Aethlon is preparing to launch the first U.S. studies
of the Hemopurifier® as a therapy to address hepatitis c virus (HCV)
based on the recent approval of an Investigational Device Exemption
(IDE) by the United States Food and Drug Administration (FDA). The
Hemopurifier is a first-in-class device that targets the rapid
elimination of infectious disease and cancer glycopathogens, including
exosomes from circulation. Exosomes enhance disease progression of
viral infections and in cancer trigger apoptosis of immune cells and
have been reported to facilitate tumor growth, metastasis, and the
development of drug resistance.
Aethlon will contribute diagnostic related technology to ESI,
including the Enzyme Linked Lectin Specific Assay (ELLSA), which has
been validated to identify the presence of exosomes underlying the human
immunodeficiency virus (HIV), tuberculosis (TB), and various forms of
cancer, including ovarian, melanoma, breast, lymphoma, and colorectal.
ELLSA was originally created by Aethlon researchers as a tool to help
validate the ability of the Hemopurifier® to capture tumor-secreted
exosomes. At the time, effective tools to isolate and quantify exosomes
did not exist as few labs conducted exosome research. Since then, an
increased understanding of the role of exosomes underlying a wide-range
of disease conditions has created a demand for related diagnostic
products. As part of the relationship, ESI has agreed to assign any
therapeutic related discoveries back to Aethlon Medical. Beyond the
potential for future technology advances by ESI researchers, ESI may
also in-license related diagnostic IP from collaborative research
partners.
The release of exosomes by viable cells has been demonstrated in
multiple cell types and systems. These nano-sized vesicles are
detectable in biologic fluids, including blood, urine, ascites, and
pleural fluids. They are essential mediators of normal homeostasis,
based on their role in intercellular communication via surface
interactions and transfer of macromolecules between cells. Cell injury
or transformation is associated with alterations in the cell's exosome
production and composition of these exosomes. This aberrant exosome
composition can be utilized as surrogate markers of specific disease
pathologies. The ESI mission is to advance an exosome-based biomarker
platform to diagnose a broad-spectrum of disease conditions as well as
monitor disease progression/regression in response to therapy as a means
to improve patient management and outcomes. In the oncology field, ESI
products will also be positioned to serve as companion diagnostics that
determine when to initiate Hemopurifier® therapy or provide real-time
monitoring of tumor responses to Hemopurifier® therapy.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address
unmet medical needs in cancer, infectious disease, and other
life-threatening conditions. Our Aethlon ADAPT™ System is a
revenue-stage technology platform that provides the basis for a new
class of devices the rapid, yet selective removal of disease promoting
particles from the entire circulatory system. At present, The Aethlon
ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address
infectious disease and cancer, and a medical device being developed
under a 5-year contract with Defense Advanced Research Projects Agency
(DARPA) to reduce the incidence of sepsis in combat-injured soldiers.
For more information, please visit
www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks
and uncertainties. Such forward-looking statements involve assumptions,
known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of Aethlon
Medical, Inc. to be materially different from any future results,
performance, or achievements expressed or implied by the forward-looking
statements. Such potential risks and uncertainties include, without
limitation, that the company can successfully protect its intellectual
property, that removal of exosomes from the human body will impact or
lead to successful treatment of cancer, or that exosomes are the cause
of tumor growth and progression, that the FDA will not approve the
initiation of the Company's clinical programs or provide market
clearance of the company's products, future human studies whether
revenue or non-revenue generating of the Aethlon ADAPT™ system or the
Aethlon Hemopurifier® as an adjunct therapy to improve patient
responsiveness to established cancer or hepatitis C therapies or as a
standalone cancer or hepatitis C therapy, the Company's ability to raise
capital when needed, the Company's ability to complete the development
of its planned products, the Company's ability to manufacture its
products either internally or through outside companies and provide its
services, the impact of government regulations, patent protection on the
Company's proprietary technology, product liability exposure,
uncertainty of market acceptance, competition, technological change, and
other risk factors. In such instances, actual results could differ
materially as a result of a variety of factors, including the risks
associated with the effect of changing economic conditions and other
risk factors detailed in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of
new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure :
The Investorideas.com is a third party publisher of news and research
Our sites do not make recommendations, but offer information portals to
research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to buy or sell
products or securities. Disclosure: Investorideas has been compensated
by AEMD for news distribution and content publishing: three thousand per
month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar
About Aethlon Medical (OTCQB: AEMD) 
About Aethlon Medical (
5 day chart
About Aethlon Medical (